APA citiranje

Rizvi, N., Barlesi, F., Brahmer, J., Felip, E., Forde, P., Garassino, M., . . . Antonia, S. (2015). Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. J Immunother Cancer.

Citação norma Chicago

Rizvi, Naiyer, et al. "Phase III, Randomized, Open-label Study of Durvalumab (MEDI4736) in Combination With Tremelimumab or Durvalumab Alone Versus Platinum-based Chemotherapy in First-line Treatment of Patients With Advanced/metastatic NSCLC: MYSTIC." J Immunother Cancer 2015.

MLA citiranje

Rizvi, Naiyer, et al. "Phase III, Randomized, Open-label Study of Durvalumab (MEDI4736) in Combination With Tremelimumab or Durvalumab Alone Versus Platinum-based Chemotherapy in First-line Treatment of Patients With Advanced/metastatic NSCLC: MYSTIC." J Immunother Cancer 2015.